Breast cancer mortality continues three-decade decline, but steeper increases for women under 50 & AAPI women of all ages

Legislation to increase access to breast and cervical cancer screening introduced in the Senate

Legislation aimed at increasing access to breast and cervical cancer screening was introduced May 22 in the U.S. Senate. The bipartisan Screening for Communities to Receive Early and Equitable Needed Services, or SCREENS, for Cancer Act would reauthorize the National Breast and Cervical Cancer Early Detection Program, or NBCCEDP, for fiscal years 2026 through 2030.

May 23, 2025

Vol.51 No.20

Clinical Roundup

Study assesses advancing racial equity in cancer care through multimodal AI

Artera, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced the publication of a validation study in the JCO Clinical Cancer Informatics on Artera’s MMAI model.

May 16, 2025

Vol.51 No.19

Clinical Roundup

Breast implant closes reconstruction gap for patients after mastectomy

Johnson & Johnson MedTech on May 13 announced the U.S. launch of MENTOR MemoryGel Enhance Breast Implants, filling a critical gap in comprehensive breast cancer care for women who have undergone a mastectomy.

May 16, 2025

Vol.51 No.19

Clinical Roundup

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Researchers at NCI have completed a comprehensive analysis of cancer statistics for different age groups in the United States and found that from 2010 through 2019, the incidence of 14 cancer types increased among people under age 50.

May 09, 2025

Vol.51 No.18

Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

April 25, 2025

Vol.51 No.16

By Richard M. Goldberg

Clinical Roundup

Enhertu demonstrates superior efficacy over standard of care in HER2+ metastatic breast cancer

The DESTINY-Breast09 phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current first-line standard of care.

April 25, 2025

Vol.51 No.16

Breast cancer mortality continues three-decade decline, but steeper increases for women under 50 & AAPI women of all ages

YOU MAY BE INTERESTED IN

Legislation to increase access to breast and cervical cancer screening introduced in the Senate

Study assesses advancing racial equity in cancer care through multimodal AI

Breast implant closes reconstruction gap for patients after mastectomy

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Regulation must keep up with scientific advances

Enhertu demonstrates superior efficacy over standard of care in HER2+ metastatic breast cancer

Renew today!

Subscriber content

Never miss an issue!

Login

Breast cancer mortality continues three-decade decline, but steeper increases for women under 50 & AAPI women of all ages

YOU MAY BE INTERESTED IN

Legislation to increase access to breast and cervical cancer screening introduced in the Senate

Study assesses advancing racial equity in cancer care through multimodal AI

Breast implant closes reconstruction gap for patients after mastectomy

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Regulation must keep up with scientific advances

Enhertu demonstrates superior efficacy over standard of care in HER2+ metastatic breast cancer

Never miss an issue!

Login

Breast cancer mortality continues three-decade decline, but steeper increases for women under 50 & AAPI women of all ages